…not insured, or at a discount if they're under-insured." Praluent's price is 46% higher than that forecast by Evercore ISI, an investment bank, and it is being approved for a larger group of patients than many Wall Street analysts expected...
Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today
TEXT-001-HOUSE_OVERSIGHT_025888.txt
p.1
View source release ↗